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ABSTRACT
Although the expression of the stem/progenitor cell marker cytokeratin-19  
(CK-19) has been associated with the worst clinical prognosis among all HCC 
subclasses, it is yet unknown whether its presence in HCC is the result of clonal 
expansion of hepatic progenitor cells (HPCs) or of de-differentiation of mature 
hepatocytes towards a progenitor-like cell phenotype. We addressed this question 
by using two rat models of hepatocarcinogenesis: the Resistant-Hepatocyte (R-H) and 
the Choline-methionine deficient (CMD) models. Our data indicate that the expression 
of CK-19 is not the result of a clonal expansion of HPCs (oval cells in rodents), but 
rather of a further step of preneoplastic hepatocytes towards a less differentiated 
phenotype and a more aggressive behavior. Indeed, although HCCs were positive for 
CK-19, very early preneoplastic foci (EPFs) were completely negative for this marker. 
While a few weeks later the vast majority of preneoplastic nodules remained CK-19 
negative, a minority became positive, suggesting that CK-19 expression is the result 
of de-differentiation of a subset of EPFs, rather than a marker of stem/progenitor 
cells. Moreover, the gene expression profile of CK-19-negative EPFs clustered together 
with CK-19-positive nodules, but was clearly distinct from CK-19 negative nodules 
and oval cells.
Conclusion: i) CK-19-positive cells are not involved in the early clonal expansion 
observed in rat hepatocarcinogenesis; ii) CK-19 expression arises in preneoplastic 
hepatocyte lesions undergoing malignant transformation; iii) CK-19 positivity in HCCs 
does not necessarily reflect the cell of origin of the tumor, but rather the plasticity of 
preneoplastic cells during the tumorigenic process.
INTRODUCTION
The heterogeneous nature of human hepatocellular 
carcinoma (HCC), which represents a serious social 
health problem [1], has so far impeded both treatment 
strategies and prognostic predictions [2]. Even though 
HCC is considered to emerge through a process of 
multistep carcinogenesis [3], its histogenesis remains 
a subject of discussion and controversy. In fact, other 
than the different etiologic factors, an important cause 
of liver cancer heterogeneity may be the cell type of 
origin. Besides a long-established idea that preneoplastic 
lesions arise exclusively from mature hepatocytes 
undergoing neoplastic transformation [4–7], it has been 
also hypothesized that a subset of HCC can originate 
from hepatic progenitor cells (HPC) [8, 9]. This subclass 
of human HCC results enriched for genes expressed 
in fetal hepatoblasts, including some progenitor cell 
markers. A progressive up-regulation of HPCs was also 
demonstrated in dysplastic nodules in human liver [10] 
and hepatocellular adenoma [11]. Moreover, numerous 
studies have reported HPCs activation in the most relevant 
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liver carcinogenic conditions in the Western world, such 
as chronic viral hepatitis and alcoholic and non-alcoholic 
fatty liver disease [12].
Although at present no single antibody can 
unambiguously define hepatic progenitor cells, several 
markers have been proposed for HPCs in HCC. In 
contrast to hepatocytes, HPCs are thought to express 
biliary markers, such as cytokeratin-7 (CK-7), 
cytokeratin-19 (CK-19), and Ov6; moreover, a subset of 
these cells expresses fetal hepatocyte (α-fetoprotein) and 
hematopoietic markers (c-kit, CD34) [8, 13].
Over the past few years, cytoskeleton-associated 
proteins have been well recognized as cellular integrators 
in the neoplastic process [14]. Different epithelia 
express characteristic combinations of cytokeratin 
proteins, depending on the organ of origin or the type 
of differentiation [15]. For example, in normal liver, 
hepatocytes express CK-8 and CK-18, whereas biliary 
epithelial cells express CK-7 and CK-19 [16, 17] as well. 
Recently, ‘stemness’-related markers have also become 
of particular relevance, as they can successfully predict 
the clinical outcome of HCC patients. In particular, the 
CK-19-positive HCC subtype is characterized by the 
worst clinical prognosis among all HCC subclasses, 
suggesting that CK-19 is a negative prognostic marker 
for HCC [9, 18]. CK-19 expression was also correlated 
with some clinicopathological features, such as poor 
tumor differentiation, metastasis, early tumor recurrence 
after resection and radiofrequency ablation [19–22]. 
Furthermore, CK-19-positive HCCs show significantly 
increased epithelial-mesenchymal transition (EMT) and 
expression of invasion-related molecules, suggesting 
that they are endowed with more invasive characteristics, 
compared to CK-19-negative HCCs [23]. In a recent study, 
Govaere et al. [24] demonstrated that in vitro primary 
human CK-19-positive tumor cells showed increased 
invasiveness and that CK-19 knockdown significantly 
reduced HCC invasive ability and rendered HCC cells 
more sensitive to cytotoxic agents, such as doxorubicin, 
5-fluorouracil and sorafenib.
An important support to the HPC hypothesis 
was derived mainly from rodent models of chemical 
hepatocarcinogenesis [25, 26]. In these models, a peri-
portal population of small epithelial cells, called oval 
cells, related to terminal biliary ductules and canals of 
Hering was described. This cell population has the ability 
to differentiate towards hepatocytes, bile ductular cells and 
intestinal epithelium and can give rise to hepatocellular 
carcinoma and cholangiocellular carcinoma.
A well-characterized rat hepatocarcinogenesis 
model is the Resistant-Hepatocyte (R-H) model, in 
which tumors are initiated by a single dose of a chemical 
carcinogen (diethylnitrosamine, DENA) and promoted 
by a brief treatment with 2-acetylaminofluorene (2-AAF) 
combined with partial hepatectomy (PH) [27]. The R-H 
model offers the possibility to identify distinct lesions 
(preneoplastic foci, preneoplastic nodules, early and fully 
developed HCCs, and occasional features of combined 
hepato-cholangiocarcinomas) at well-defined timings. 
Interestingly, a modification of the R-H model, consisting 
in the omission of DENA initiation, has been extensively 
used in studies of activation, expansion and differentiation 
of oval cells [28]. Therefore, the advantage of the R-H 
model is that it allows not only examining the expansion 
of both preneoplastic and oval cells at the same time, but 
also investigating the evolution of the early preneoplastic 
lesions to fully developed HCC. Recently, comparative 
functional genomics has shown a stringent clustering 
of CK-19-positive preneoplastic nodules and advanced 
HCCs obtained from the R-H model with human HCCs 
characterized by poor prognosis [29, 30].
Although these findings suggest that CK-19-positive 
HCCs could originate from progenitor cells, some reports 
cast doubt on the progenitor cell origin of CK-19-positive 
HCC [31, 32]. Therefore, it remains elusive whether the 
expression of CK-19, as well as of other HPC markers, 
represents i) retention of a progenitor cell phenotype all 
throughout the carcinogenic process or ii) the result of 
de-differentiation of preneoplastic or malignant 
hepatocytes to a progenitor cell/biliary phenotype during 
progression towards HCC.
The aim of the present study was to analyze the early 
changes in the R-H model of carcinogenesis in order to 
investigate the relationship between oval cell proliferation 
and EPFs, as well as to understand whether in this protocol 
CK-19 expression is built-in in clonally expanding EPFs 
or if it is acquired through a progressive de-differentiation 
of preneoplastic hepatocytes towards a progenitor cell 
phenotype. The latter question was also addressed by using 
another rat model of hepatocarcinogenesis consisting of a 
chronic exposure to a steatogenic environment generated 
by a choline devoid-methionine deficient diet (CMD) [33].
RESULTS
mRNA expression profiling of oval cells is 
distinct from that of early preneoplastic 
foci (EPFs)
While several works suggest that oval cells can 
differentiate to hepatocytes [25, 26, 28], the role of 
oval cells in the development of HCC is a controversial 
matter [4, 5, 31, 34–37]. To explore this issue, we 
used the Resistant-Hepatocyte (R-H) rat model [27] 
(Supp. Figure 1A). This model is characterized by a 
synchronous expansion of carcinogen-initiated cells that 
can be easily identified by preneoplastic markers (such as 
the expression of GSTP) as early as 3–7 days after PH. 
Unlike normal hepatocytes, preneoplastic hepatocytes are 
able to divide after 2/3 PH, in the presence of the cytostatic 
environment generated by 2-AAF. Concomitantly, 
resection of 2/3 of the liver in the presence of 2-AAF 
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causes a massive expansion of oval cells, expressing 
markers specific for biliary epithelial cells, such as 
CK-19, GSTP and gamma-glutamyltranspeptidases. 
Notably, while oval cells, like GSTP-positive hepatocyte 
preneoplastic lesions, are completely absent prior to PH, 
a concomitant surge of both these two cell populations 
is observed 2–3 days after PH. Using this model, we 
performed gene expression profiling in micro-dissected 
oval cells and early preneoplastic foci (EPFs) appearing 
7 days after PH. EPFs appeared as small spherical lesions 
consisting of 15 to 100 hepatocytes, with basophilic cells 
characterized by prominent nucleoli. Mitotic figures 
were often present. A total of 1,570 out of 21,791 genes 
included in the array were detected, according to the 
parameters described in Supplementary Material. 
Hierarchical cluster analysis stratified rat lesions into two 
major clusters: 1) oval cells; 2) normal liver and EPFs; 
within the second cluster, normal liver (CO) and EPFs 
formed 2 distinct sub-clusters (Figure 1A). Notably, 
among the significantly dysregulated genes (at least 
2 fold change difference), 69% were exclusive of either 
oval cells or EPFs (Figure 1B, 1C). Quantitative RT-PCR 
validation performed on a few genes typically expressed 
by oval cells (Epcam and CK-19) or mainly expressed 
by mature hepatocytes (Nqo1) confirmed microarray 
expression data (Figure 1D). These results show that oval 
Figure 1: mRNA profile of oval cells and EPFs in the R-H model of hepatocarcinogenesis. A. Hierarchical clustering of 
1,570 genes in normal liver (CO), laser-microdissected oval cells and early preneoplastic foci (EPFs) 7 days after PH. Each row represents 
the expression profile of a gene and each column represents a sample from pools of microdissected oval cells or EPFs. Controls and different 
types of lesions are indicated by colored bars. Only mRNAs whose expression was dysregulated more than 2-fold were considered. Red 
and green colors represent higher or lower expression levels of the mRNA (median-centered), respectively. B. Number of differentially 
expressed mRNAs in oval cells and EPFs compared to age-matched controls, defined by P < 0.05 (BH-corrected). RNA was extracted 
from laser-microdissected oval cells and EPFs occurring 7 days after PH and CK-19-positive and CK-19-negative nodules generated 
7 weeks after surgery. C. Venn diagrams illustrating significantly dysregulated genes in oval cells and EPFs. D. QRT-PCR validation of 
CK-19, Epcam and Nqo1 in controls, oval cells and EPFs. Gene expression is reported as fold-change relative to age-matched controls. 
***P < 0.001, **P < 0.01, *P < 0.05, NS: not significant.
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cells have an expression profile clearly distinct from that 
of hepatocyte EPFs and suggest that they are not the cells 
of origin of EPFs.
Oval cells but not early preneoplastic foci (EPF) 
show positivity to CK-19
Our gene expression analysis showed that, unlike 
other biliary markers up-regulated in EPFs (GSTP, GGT), 
CK-19 was poorly expressed in these lesions, suggesting 
this marker is not a built-in feature of precursor populations 
of HCC. Since our microarray was performed on pools 
of EPF, it was not possible to rule out the possibility 
that CK-19 was expressed in a small fraction of them. 
To investigate more in depth CK-19 expression in EPFs, 
we performed immunohistochemistry (IHC) analysis of 
CK-19 expression in oval cells and EPFs at 3 and 7 days 
after surgery. As seen in Figure 2A, while CK-19 positivity 
was detected in the vast majority of proliferating oval 
cells - which rapidly expand after PH in the presence 
of 2-AAF - IHC of more than 400 hepatocyte foci 
(performed on serial cryostat liver sections 3 and 7 days 
after PH) revealed that 100% of the GSTP-positive EFPs 
were completely negative for CK-19 (Figure 2B, 2C). 
The observation that no oval cells could be detected 
prior to PH and the concomitant presence of both this 
cell population and EPFs as early as 3 days after surgery, 
further suggest that EPFs do not derive from oval cells.
CK-19 expression is acquired by a subset of 
nodules during their transition from a focal to a 
nodular stage
The first evidence of CK-19 positivity was found 
5 weeks after DENA (that is, 7 days after 2-AAF release); 
at that time, very few CK-19-positive preneoplastic 
nodules were detected in a context of otherwise negative 
lesions (19 CK-19+/250 GSTP+ nodules; 7.60%) 
Figure 2: Early preneoplastic foci (EPFs) are negative for CK-19. A. Photomicrograph illustrating CK-19 staining in bile ducts 
of control liver and proliferating oval cells 3 and 7 days after PH (CK-19, X10). Serial sections stained for hematoxylin-eosin (H&E) 
are depicted above (magnification X10). B. GSTP-positive EPFs developed 3 days after PH (left) are completely negative for CK-19 
(magnification X4, left; X10, right). Few CK-19- positive oval cells are present. C. Photomicrograph showing that none of the GSTP+ 
EPFs occurring 7 days after PH are positive for CK-19 (magnification X1.25, left; X4, right). Several CK-19 positive oval cells are present.
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Figure 3: CK-19 positivity is acquired along with the progression from EPFs to a nodular stage. A. Photomicrograph 
showing GSTP and CK-19 staining in preneoplastic lesions 2 weeks after PH (magnification X10). B. Photomicrograph showing occasional 
CK-19 staining in a nodule 2 weeks after PH (magnification X10), C. A GSTP-positive nodule showing a large number of cells positive for 
CK-19 at 7 weeks after PH (magnification X10).
(Figure 3A, 3B). In agreement with previous works 
[29, 30], at a later time point (10 weeks after carcinogen 
administration), about 25% of GSTP positive nodules 
showed positivity for CK-19 (Figure 3C). These nodules 
closely resemble human dysplastic nodules as they display 
hepatocytes with large eosinophilic cytoplasm and evident 
nucleoli [38]. These lesions often compress adjacent 
parenchyma and show distorted architecture. EPFs and 
CK-19+ nodules were characterized by a diffuse positivity 
to 5-bromo-2′ deoxyuridine (BrdU), which is indicative 
of very high proliferative activity (Supp. Figure 2A, 2B); 
however, unlike EPFs, they exhibited the presence 
of several cells positive for the cleaved form of 
caspase-3 (Cas-3) (Supp. Figure 3A, 3B, 3D), a typical 
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feature of advanced HCC (Supp. Figure 3C, 3D). 
Measurement of Cas-3 positive cells resulted in an 
apoptotic index (AI) of 0.01/field in EPFs, 4/field in 
CK-19+ nodules and 15/field in HCC. On the contrary, 
CK-19-negative nodules, accounting for the vast majority 
of the lesions observed at this time point, resemble 
regenerative nodules in a cirrhotic-like background and 
did not exhibit major cytological and/or architectural 
dysplastic changes. In agreement with our previous 
studies [39], they also showed a much lower number 
of BrdU-positive hepatocytes (Supp. Figure 2B), and 
virtually no positivity for caspase-3 (apoptotic index was 
0.4/field) (Supp.  Figure 3B and 3D).
CK-19-negative EPFs exhibit a gene expression 
profile similar to CK-19-positive nodules 
and HCCs
It has been shown that CK-19-positive preneoplastic 
nodules exhibit a similar global expression profile to 
that of advanced HCCs, while CK-19-negative nodules 
co-cluster together with the control liver [30]. Therefore, 
we wished to investigate and compare the expression 
profile of early CK-19-negative EPFs with that of 
CK-19-positive and CK-19-negative preneoplastic 
nodules. Gene expression profiling was performed using 
the same early foci described above, and preneoplastic 
nodules CK-19-positive and CK-19-negative obtained 
10 weeks after initiation. A total of 1,310 out of 21,791 
genes included in the array were selected, as described in 
Supporting Material. Hierarchical cluster analysis stratified 
the lesions into two major clusters: 1) normal liver (CO) 
and preneoplastic CK-19-negative nodules; 2) CK-19-
negative EPFs and CK-19-positive nodules (Figure 4A). 
As shown in the Venn diagram, EPFs and CK-19-positive 
nodules, unlike CK-19-negative nodules, exhibited a 
high number of modified genes compared to control 
livers (Figure 4B, 4C). Notably, while 324 genes were 
exclusively altered in EPFs and 183 in CK-19-positive 
preneoplastic nodules, 246 dysregulated genes were shared 
between EPFs and CK-19-positive nodules; only 5 genes 
were uniquely modified in EPFs and CK-19-negative 
nodules. These data suggest that EPFs are very likely to 
evolve directly to CK-19-positive preneoplastic lesions, 
Figure 4: mRNA profile of EPFs, CK-19-positive and CK-19-negative nodules. A. Hierarchical clustering of 1310 genes in 
normal liver (CO), EPFs and CK-19-positive and CK-19-negative nodules. Each row represents the expression profile of a gene. Columns 
represent a single sample for CK-19-positive and negative nodules and controls, and a pool of 10–15 EPFs. Controls and nodules are 
indicated by colored bars. Only mRNAs whose expression was dysregulated more than 2-fold were considered. Red and green colors 
represent higher or lower expression levels of the mRNA (median-centered), respectively. B. Number of differentially expressed mRNAs 
in EPFs, CK-19-positive and CK-19-negative nodules compared to age-matched controls, defined by P < 0.05 (BH-corrected). RNA was 
extracted from laser-microdissected early preneoplastic foci (EPFs) occurring 7 days after PH and CK-19-positive and CK-19-negative 
nodules generated 7 weeks after surgery. C. Venn diagrams illustrating overlapping subsets of significantly dysregulated genes in EPFs, CK-
19-positive and CK-19-negative preneoplastic nodules. D. Microarray analysis of mRNA levels of Nrf 2-target genes in CK-19-negative 
EPFs developed 7 days after surgery. Values are expressed as fold increase compared to livers from age-matched controls.
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while CK-19-negative nodules - whose expression profile 
is close to normal liver - are probably lesions transitioning 
towards a fully differentiated phenotype.
Among the differentially expressed genes, 16/20 of 
the most up-regulated (fold change versus controls >5) 
(Table 1) and 16/42 of the most down-regulated (fold 
change versus controls <5) genes in EPFs were the 
most dysregulated in CK-19-positive nodules as well 
(Table 2). Among the up-regulated genes in both EPFs and 
CK-19-positive nodules, target genes of the Nrf 2-Keap1 
pathway were the most frequent (Figure 4D) indicating 
that activation of this pathway plays a critical role in the 
clonal expansion of initiated cells and their progression to 
malignancy. Remarkably, analysis of transcription factor-
dependent pathways revealed that, when compared to 
EPFs and CK-19-positive nodules, CK-19-negative lesions 
showed a significant decrease of Nrf 2-pathway activation 
(51 and 48 dysregulated genes vs. 19 respectively) 
(Supp. Figure 4), suggesting that sustained activation of 
this pathway is linked to cancer development.
Notably, microarray analysis showed that the most 
dysregulated genes in EPFs matched with those previously 
identified in advanced HCC (Supp. Table 1 and Ref. 30). 
Quantitative RT-PCR validation performed on the three 
most up-regulated and the three most down-regulated 
genes in EPFs and HCCs confirmed microarray expression 
data (Supp. Figure 5). These results further support the 
notion that the major expression changes observed in HCC 
occur in the very first stages of the tumorigenic process.
In conclusion, the results demonstrate that the 
expression profile of CK-19-negative EPFs is essentially 
similar to that of CK-19-positive nodules developed 
6 weeks later, and that activation of the Nrf 2/Keap1 
pathway might dictate the fate of EPFs (persistency 
and progression vs. remodeling). They thus suggest that 
CK-19-positive hepatocytes do not originate from liver 
Table 1: Most up-regulated genes (>5)
Gene symbol FC EPFs/ctr Gene symbol FC CK-19+/ctr
Gstp1 105.82 Gstp1 102.24
Abcb1 29.70 Gstp2  41.96
Akr7a3 26.79 Akr1b8  35.36
Gstp2 26.37 Defb1  34.28
Akr1b8 25.67 Akr7a3  29.13
Yc2 18.32 Ca2  26.91
Slc25a4 15.48 Aldh1a1  18.13
Cyp2c40 12.35 Nqo1  17.41
Aldh1a1 10.25 Abcb1  16.26
Gpx2  9.52 Pcp4  15.45
Ca2  9.27 Gclc  13.63
Smp2a  9.26 Cyp2c40  12.86
Nqo1  9.01 Nefl  12.82
Abcc3  6.91 Abcc3  12.79
A2m  5.96 Yc2  12.79
Gclc  5.64 Ltb4dh  12.76
Ltb4dh  5.41 Gpx2  12.36
Mt1a  5.33 Krt1–19   9.93
Ephx1  5.20 Maf   8.96
Atp6v1d  5.12 Slc25a4   8.15
Ddit4l   7.62
Gclm   6.83
(Continued )
Oncotarget38756www.impactjournals.com/oncotarget
Gene symbol FC EPFs/ctr Gene symbol FC CK-19+/ctr
Cd24   6.79
Tubb6   6.70
S100a11   6.58
Cryl1   6.28
Slc17a3   6.15
Ephx1   6.15
Slc20a1   6.15
Ctse   6.05
Anxa2   6.00
Bzrp   5.71
Igfbp1   5.56
Ugdh   5.45
Ugt1a6   5.39
Tacstd1   5.12
Genes in bold are up-regulated in EPFs and in CK-19+ nodules as well. Gene expression is reported as fold-change relative 
to age-matched controls.
Table 2: Most down-regulated genes (<−5)
Gene symbol FC EPFs/ctr Gene symbol FC CK-19+/ctr
G6pc −5.10 Cyp4a14 −4.91
Amacr −5.13 Akr1c21 −5.66
Baat −5.16 G0s2 −6.18
Ust5r −5.22 Cyp8b1 −6.20
Cyp2b15 −5.31 Ust5r −6.55
Pgcp −5.46 Ste2 −6.60
Sez6 −5.51 Cyp2c7 −6.62
Cyp2c7 −5.57 G6pc −6.95
Ndrg2 −5.60 Cyp2c37 −7.08
Dio1 −5.72 Aox3 −7.09
Slc27a5 −5.73 Hao2 −7.39
Avpr1a −5.76 Avpr1a −7.40
Oat −5.84 Cyp3a11 −7.57
Slco1b2 −5.89 Cyp1a2 −7.59
Rnase4 −5.91 Oat −7.99
Thrsp −6.34 Slc27a5 −8.09
Hba-a1 −6.36 Olr59 −8.42
Gnmt −6.54 Fabp7 −8.42
Hbb −6.59 Ca3 −8.52
Cyp3a13 −6.84 Cyp3a3 −9.02
(Continued )
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progenitor cells, but are the result of a reprogramming of 
mature, although altered, hepatocytes.
Expression of CK-19 is acquired late in the 
carcinogenic process also in the CMD protocol
To investigate whether the lack of CK-19 expression 
in early stages of HCC development is unique to the R-H 
model of hepatocarcinogenesis, we studied a different 
rat model, consisting of a choline-devoid methionine-
deficient diet [33] (Supp. Figure 1B), and characterized 
by extensive fatty liver. IHC analysis showed that in this 
model early foci appearing 10 weeks after initiation, 
as well as preneoplastic lesions detected 4 months 
after DENA, were also completely negative for CK-19 
(Figure 5A, 5B). However, a diffuse CK-19 positivity 
was detected in 8/8 HCCs arising after 13 months of 
CMD diet feeding (Figure 5C). These results further 
support the concept that CK-19-positive hepatocytes are 
the consequence of a reprogramming of mature, although 
altered, hepatocytes.
DISCUSSION
In this work we addressed the question of the origin 
of HCC cells in the context of the rat R-H and CMD models 
of hepatocarcinogenesis. The R-H model is characterized by 
the proliferation of oval cells soon after PH in the presence 
of the cytostatic environment generated by 2-AAF [27]. 
An increased number of oval cells, positive for CK-19 
and other biliary markers, was observed up to 3–4 weeks 
after surgery [34]. For this reason, it has been hypothesized 
that preneoplastic cells derive from proliferating oval 
cells [35, 36]. Indeed, in the R-H model, most of HCCs are 
CK-19-positive while the majority of preneoplastic lesions 
are negative for this marker and are believed to undergo 
spontaneous regression, further suggesting that CK-19-
positive lesions are the precursors of HCCs [27].
Gene symbol FC EPFs/ctr Gene symbol FC CK-19+/ctr
Pklr   −7.06 Cyp3a13 −9.96
Mup5   −7.10 Cdh17 −10.20
Scd1   −7.30 Cyp3a1 −11.57
Serpina3m   −7.46 Dhrs7 −14.86
Ang1   −7.48 Cyp2c −15.48
Mug2   −7.67 Obp3 −41.11
Olr59   −7.77
Fabp7   −7.87
Aox3   −7.89
Serpina4   −7.96
Ces3   −8.77
Sult1c1   −9.18
Ppp1r3b   −9.52
Ste2   −9.56
Spin2b   −9.90
Hao2  −10.87
Apoa2  −11.14
Mup4  −18.26
Ca3  −20.20
Dhrs7  −30.23
Obp3  −62.76
Cyp2c −115.98
Genes in bold are down-regulated in EPFs and in CK-19+ nodules as well. Gene expression is reported as fold-change 
relative to age-matched controls.
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Data obtained from this as well as other rodent 
HCC models raised considerable discussion about the 
involvement of hepatic progenitor cells (oval cells in 
rodents) in liver carcinogenesis. Indeed, while Sell et al. 
[35, 36] postulated that the sequence of hepatocyte foci to 
nodules of increasing size and then to HCC most likely 
originates from bipotential oval cells, Anilkumar et al. [31] 
demonstrated an independent development of the ductular 
oval cell response and the emergence and expansion of 
foci in the R-H model.
Trying to shed light on this relevant topic, we 
decided to further dissect the R-H model, analyzing 
lesions occurring before the appearance of preneoplastic 
nodules. We thus examined foci appearing 3 days after 
PH. These lesions, identified by GSTP staining, consist 
of about 15–20 cells on average, with features typical of 
hepatocytes (large round nuclei and evident basophilic 
cytoplasm); of the over 400 early preneoplastic foci 
examined, none displayed CK-19 positivity, not even in 
single cells. However, the surrounding liver presented 
many CK-19-positive cells with clear oval cell phenotype. 
Four days later, we observed an obvious enlargement 
of the foci, which still remained totally negative for 
CK-19. When we analyzed preneoplastic lesions (2 weeks 
after PH), while almost all the nodules were consistently 
negative, we detected for the first time a limited number 
of lesions exhibiting CK-19 positivity (19/250; 7.6%). 
Also in these nodules, CK-19-positive cells maintained 
a typical hepatocyte phenotype. Seven weeks after 
PH, the liver was almost completely occupied by large 
nodules, a quarter of which were positive for CK-19. It is 
important to underline that CK-19-positive nodules, on 
average, contained more than 25% CK-19-positive cells. 
This is hardly in agreement with the hypothesis that the 
CK-19-positive cells might represent HCC cancer stem 
cells. This idea is further enforced by the observation 
that most of HCCs appearing 10–14 months after DENA 
administration are characterized by CK-19 positivity 
Figure 5: CK-19 positivity is a late event in the tumorigenic process induced by the CMD protocol of  
hepatocarcinogenesis. Photomicrographs showing absence of CK-19 staining in: A. EPFs and B. preneoplastic nodules, occurring 
10 week and 4 months after DENA treatment and strongly positive for GSTP. C. H&E (left) Photomicrograph of a typical HCC developed 
13 months after initiation (H&E, X20, left) showing a large number of CK-19-positive cells (middle, X10); larger view of the same HCC 
(right, X20).
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and express a high number of hepatocytes positive for 
this marker.
All these data suggest that the neoplastic lesions 
observed in the R-H model originate from CK-19-negative 
cells and that they acquire the expression of this marker 
only later, during the tumorigenic process (Figure 6). 
Similar data were also obtained in a different rat model 
consisting of feeding rats with a CMD diet, whereby 
lesions develop in a steato-necrotic environment caused by 
a choline devoid-methionine deficient diet. In fact, while 
HCCs are definitely CK-19-positive, no cells stained for 
this marker were observed at early or intermediate stages 
of the carcinogenic process.
Altogether these data suggest that not only normal 
liver cells but also neoplastic hepatic cells maintain a 
high level of plasticity, being able to acquire/lose markers 
considered restricted to defined cell types. Furthermore, 
we believe that this is very important from a translational 
point of view because it implies that markers/phenotypes 
observed in advanced cancers do not necessarily reflect the 
cell of origin of the tumor; they might instead be acquired/
lost due to differences in the environment or to the distress 
conditions often present during tumorigenesis. This can be 
particularly true for molecules, like cytokeratins, which 
are involved in the maintenance of cyto-architecture and 
are particularly sensitive to mechanical stress [40].
Camargo and colleagues have recently shown that 
adult hepatocytes have the potential to give rise to cells that 
molecularly and functionally resemble liver progenitors or 
‘‘oval’’ cells [41]. The observation that a large proportion 
of hepatocytes can undergo dedifferentiation suggests that 
most hepatocytes intrinsically harbor this developmental 
capacity. In our work we show that not only normal 
adult hepatocytes are inherently plastic and might 
Figure 6: Representative scheme of the multistage tumorigenic process in the R-H model. Exposure of rat liver to the 
R-H protocol gives rise to early preneoplastic foci (EPFs) and oval cells. While all EPFs are virtually negative for CK-19, two distinct 
types of nodules arise later on during the tumorigenic process: 1) CK-19-positive (a minority) and CK-19-negative (the majority) nodules. 
CK-19-positive nodules exhibit an expression profile very similar to that of EPFs and HCC, suggesting that they represent the precursor 
cell population of HCC. In contrast, most of the CK-19-negative nodules undergo remodeling and disappear. Few negative HCCs can be 
observed which probably originate from CK-19-negative nodules. Oval cells which actively divide during the first week post-surgery are 
no longer visible 3–4 weeks after PH. Occasionally, they can give rise to cholangiocarcinomas.
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dedifferentiate into a progenitor-like cell type, but that 
this property is maintained also by hepatocytes “primed” 
toward malignancy. These findings are of particular 
relevance also for human pathology, as CK-19-positive 
HCCs, endowed with worse prognosis, are believed to 
derive from oval cells or CK-19-positive progenitor cells. 
In this context, the analysis of the expression profiles 
performed in this work further reinforces the idea that the 
R-H neoplastic lesions do not originate from oval cells. 
As shown in Figure 1A, in fact, expression profiles of 
early foci and oval cells are clearly distinct, while early 
foci co-cluster with control hepatocytes. It would be 
interesting to perform similar analyses in human livers 
as well, in order to verify the origin of CK-19-positive 
tumors directly.
Another interesting point stemming from the present 
work is the evolutionary landscape of progressive lesions 
in the R-H model. Expression profiles show that EPFs 
co-cluster with CK-19-positive nodules, while CK-19-
negative ones are more similar to normal liver. In this frame, 
we can hypothesize that, upon the carcinogenic stimulus, 
hepatocytes undergo a profound metabolic change that is 
required for further progression. Indeed, in other works 
we have shown that the gene expression profile of CK-19-
positive nodules is very similar to that of advanced HCC [29, 
30]. CK-19-negative nodules, instead, undergo remodeling, 
as testified by a progressive loss of neoplastic markers (such 
as GSTP, GGT), and reacquisition of an expression pattern 
typical of normal hepatocytes; these phenotypic changes 
precede nodule disappearance [42, 43]. Notably, a similar 
alternative fate of hepatic dysplastic nodules has been 
observed in humans. Indeed, as reported by Roncalli et al., 
only a minority of regenerative/dysplastic nodules undergo 
malignancy, while 40–60% stabilize, and a few definitely 
disappear during patients’ follow-up [44].
Although the mechanisms responsible for 
the alternative fate of preneoplastic nodules are 
unknown, it is interesting to note that many of the genes 
found up-regulated in both EPFs and CK-19-positive nodules 
are targets of Nrf 2, a transcriptional factor that upon nuclear 
translocation induces the expression of genes involved in 
cytoprotection and proliferation [45–47]. The finding that 
the Nrf 2-Keap1 pathway is activated in very early and small 
preneoplastic foci and that its activation persists only in 
those nodules that are considered precursors of HCC in the 
R-H model [30] makes Nrf 2 an interesting and promising 
therapeutic target in HCC therapy and suggests its potential 
prognostic use for the identification of progressive lesions 
in human HCC development. Notably, our very recent data 
obtained in the R-H model showed that activation of NRF2/
KEAP1 pathway, due either to down-regulation of miRNA-
200a, which targets KEAP1, or to extremely frequent 
missense mutations of NRF2, characterizes preneoplastic 
nodules and persists all throughout the process up to HCC 
development [48]. In the same study, we also showed 
that following injection of NRF2-silenced HCC cells into 
syngeneic rats, the tumorigenic capacity of a rat HCC cell 
line was completely abolished.
In conclusion, our present results obtained in two 
different rat models of hepatocarcinogenesis demonstrate 
that CK-19 expression is not intrinsic to preneoplastic cells, 
but is acquired later in the tumorigenic process, and does 
not necessarily predict the cell origin of HCC. This work 
thus demonstrates that not only normal adult hepatocytes 
but also preneoplastic ones are inherently plastic and can 
acquire markers of more indifferentiated cells.
MATERIALS AND METHODS
Animals and treatment
R-H protocol
Male Fischer rats were obtained from Charles River, 
Milano, Italy. Guidelines for Care and Use of Laboratory 
Animals were followed during the investigation. 
All animal procedures were approved by the Ethical 
Commission of the University of Cagliari and the Italian 
Ministry of Health. Animals were treated with a single 
dose of diethylnitrosamine (DENA, 150 mg/kg, Sigma-
Aldrich, Milano, Italy) and, two weeks later, were 
subjected to the R-H protocol, consisting of a 2-week diet 
supplemented with 0.02% 2-acetylaminofluorene (2-AAF) 
and a two/thirds partial hepatectomy (PH) [27]. Rats were 
sacrificed 3 or 7 days after PH or switched to basal diet all 
throughout the experiment and sacrificed 5 and 10 weeks 
after DENA administration (Supp. Figure 1A).
CMD protocol
Four week-old male F-344 rats (90–100grams) were 
given DENA (150 mg/kg) and 2 weeks later fed a choline-
methionine deficient (CMD) diet [33]. Rats were sacrificed 
10 weeks and 4 and 13 months after DENA administration 
(Supp. Figure 1B).
Immunohistochemistry
Immediately after sacrifice, liver sections were 
fixed in 10% formalin or snap-frozen in liquid nitrogen 
and processed for hematoxylin-eosin, cresyl violet, 
GSTP, CK-19, and BrdU immunohistochemistry, as 
described [30]. We defined CK-19-positive nodules as 
all those lesions exhibiting a CK-19-positive area of at 
least 5% of the total area of the preneoplastic lesion (the 
criteria commonly used by pathologists). The average 
area occupied by CK-19-positive hepatocytes was 
higher than 25% of the total area of the preneoplastic 
nodules. We considered as CK-19-negative all those 
lesions which did not exhibit any CK-19-positive cells 
within the preneoplastic lesion, either EPFs or nodules. 
Immunostaining for the cleaved form of caspase 3 was 
performed to detect cell death, according to Eckle et al 
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[49]. The apoptotic index is expressed as number of 
cleaved-caspase-3 (Cas-3) positive cells/field (20x). 
30 EPFs, 12 CK-19+ nodules and 36 CK-19- nodules were 
scored.
Laser-capture micro-dissection (LMD)
we microdissected 60 foci (1 week after PH), 
10 nodules (10 weeks after initiation with DENA), 
and random areas from the liver of rats exposed to the 
R-H protocol. Oval cells, identified on morphological 
criteria after staining with cresyl violet and H&E, and by 
immunohistochemistry (CK-19, GSTP, GGT), were then 
microdissected from cresyl violet stained sections 1 week 
after PH (for details see Supp. Material).
mRNA expression profiling
RNA was extracted and purified from oval 
cells or preneoplastic foci and nodules after laser 
microdissection from the liver of four to five animals. For 
the gene expression profile, 150 ng of RNA were amplified 
(Illumina TotalPrep RNA Amplification Kit), labeled 
and hybridized on Illumina microarray (RatRef-12 V1 
BeadChips, Illumina Inc., San Diego, CA, USA), including 
21.791 genes (for further details and data analysis see 
Supporting Material). mRNAs validation was performed 
using specific TaqMan assays (Applied Biosystems). To 
identify the differentially expressed genes in each type 
of group towards its age-matched control we applied the 
Random-Variance Model and Multivariate Permutation 
Test. Raw microarray data have been deposited in the GEO 
database (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE70322) with Accession Number GSE70322.
qRT-PCR analysis
RNA was retro-transcribed using the High Capacity 
cDNA Reverse Transcription Kit (Life Technologies). 
Analysis of Epcam, CK-19, Nqo1, Akr1b8, Defb1, Gstp1, 
Ca3, Dhrs7 and Hao2 was performed using specific 
TaqMan probes (Life Technologies) and GAPDH as the 
endogenous control.
Statistical analysis
One-way analysis of variance (ANOVA) and 
Student’s t-test were used to analyze the data (Instat; 
GraphPad, San Diego, CA, USA). The results of 
observations are presented as the means ± SE. A value of 
P < 0.05 was regarded as a significant difference between 
groups.
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